The company's revenue declined by 16.2% in 2024Q4, while operating expenses of $1.6 million resulted in a deeply negative operating margin of 85.5%.
| Sales/Revenue | 2.79M | 4.73M | 5.43M | 5.14M | 5.94M | 4.12M |
| Revenue Growth % | - | -13.01% | 5.78% | -13.59% | 44.34% | - |
| Cost of Goods Sold | 0 | - | - | - | - | - |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 735.96K | 955.85K | 1.83M | 1.68M | 1.54M | 1.02M |
| Gross Margin % | 26.35% | 20.22% | 33.63% | 32.74% | 25.87% | 24.89% |
| Gross Profit Growth % | - | -47.68% | 8.63% | 9.35% | 50.05% | - |
| Operating Expenses | 3.39M | 11.68M | 2.99M | 1.64M | 1.14M | 826.02K |
| OpEx % of Revenue | - | 247.17% | 54.99% | 31.93% | 19.16% | 20.06% |
| Selling, General & Admin | 3.39M | 11.68M | 2.99M | 1.64M | 1.14M | 826.02K |
| SG&A % of Revenue | - | 247.17% | 54.99% | 31.93% | 19.16% | 20.06% |
| Research & Development | 0 | - | - | - | - | - |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | - | - | - | - | - |
| Operating Income | -2.85M | -10.73M | -1.16M | 42.24K | -504.91K | 198.76K |
| Operating Margin % | -101.98% | -226.95% | -21.35% | 0.82% | -8.49% | 4.83% |
| Operating Income Growth % | - | -824.69% | -2846.08% | 108.37% | -354.03% | - |
| EBITDA | -1.41M | -10.23M | -953.74K | 271.95K | -200.96K | 541.3K |
| EBITDA Margin % | -50.37% | -216.38% | -17.55% | 5.29% | -3.38% | 13.14% |
| EBITDA Growth % | - | -972.31% | -450.7% | 235.32% | -137.13% | - |
| D&A (Non-Cash Add-back) | 346.85K | 499.5K | 206.26K | 229.71K | 303.94K | 342.54K |
| EBIT | 764.7K | 10.35M | -182K | 154.6K | 421.75K | 244.47K |
| Net Interest Income | 652.6K | -614.17K | -772K | -45.66K | -77.74K | -88.23K |
| Interest Income | 1.1M | 2.25K | 6.95K | 518 | 21 | 63 |
| Interest Expense | 446.36K | 616.42K | 778.66K | 46.18K | 77.76K | 88.29K |
| Other Income/Expense | 0 | - | - | - | - | - |
| Pretax Income | -896.62K | 9.73M | -961K | 108.42K | 500.65K | 156.18K |
| Pretax Margin % | -32.1% | 205.84% | -17.69% | 2.11% | 8.42% | 3.79% |
| Income Tax | -487K | 0 | -487K | 0 | 208.14K | 294.72K |
| Effective Tax Rate % | 54.32% | 0% | 50.68% | 0% | 41.57% | 188.7% |
| Net Income | -461.62K | 9.88M | -525K | 130.19K | 458.67K | -533 |
| Net Margin % | -16.53% | 209.02% | -9.66% | 2.53% | 7.72% | -0.01% |
| Net Income Growth % | - | 1981.79% | -503.25% | -71.61% | 86153.85% | - |
| Net Income (Continuing) | -409.6K | 9.73M | -474K | 108.42K | 135.85K | -138.53K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -433.14K | -644.83K | -433.14K | -490.05K | -462.43K | -138.97K |
| EPS (Diluted) | -0.78 | 16.80 | -22.31 | 12.44 | 62.52 | -0.00 |
| EPS Growth % | - | 175.32% | -279.38% | -80.11% | - | - |
| EPS (Basic) | - | 16.80 | -22.31 | 12.44 | 62.52 | -0.00 |
| Diluted Shares Outstanding | 588.24K | 588.24K | 588.24K | 262.19K | 262.19K | 262.19K |
| Basic Shares Outstanding | 588.24K | 588.24K | 588.24K | 262.19K | 262.19K | 262.19K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Imminent liquidity and regulatory risk
As reported in recent financial filings, NIVF experienced a 16.2% year-over-year revenue decline in 2024Q4, signaling significant challenges in maintaining its patient acquisition pipeline within the highly competitive and volatile cross-border medical tourism market, particularly as demand from Chinese outbound travelers remains notably inconsistent.
The persistent revenue volatility suggests that the company's reliance on discretionary, project-based fertility services leaves it highly exposed to macroeconomic shifts. Investors should monitor whether this downward trend reflects a structural loss of market share or merely a temporary disruption in international travel patterns.
Based on the company's 2024Q4 income statement, operating expenses of $1.6 million continue to dwarf gross profits, resulting in a negative operating margin of 85.5% that highlights a fundamental inability to scale the business model efficiently relative to its current administrative and clinical overhead.
The lack of operating leverage indicates that the company's fixed-cost structure is currently misaligned with its revenue generation capacity. Without a substantial increase in patient throughput, the firm appears trapped in a cycle where administrative costs continue to erode any potential gains from clinical service delivery.
According to historical data, the company has frequently reported net income figures that diverge sharply from operating performance, suggesting that reported bottom-line results are heavily influenced by non-recurring accounting adjustments rather than sustainable, core operational profitability or underlying clinical service demand.
The disconnect between operating losses and net income volatility warrants extreme caution, as it implies that the company's reported earnings are not representative of its actual cash-generating ability. Analysts should focus exclusively on operating income to gauge the true health of the business.
As indicated by the company's limited cash reserves of approximately $758,621, the current burn rate poses a severe threat to the firm's ongoing viability, suggesting that the business may require immediate external financing to avoid a potential liquidity crisis in the near term.
Short-sellers would likely focus on the mismatch between the company's high-risk regulatory arbitrage model and its deteriorating financial position. The reliance on non-operating gains to mask operational deficits suggests that the current valuation may not be supported by the underlying fundamentals of the clinical business.
Quick answers to the most common questions about buying NIVF stock.
For fiscal year 2025, NewGenIvf Group Limited (NIVF) reported total revenue of $4.7M. This represents a 14.8% increase compared to $4.1M in 2021.
NewGenIvf Group Limited (NIVF) is profitable, generating $9.9M in net income for the fiscal year ending 2025 with a net profit margin of 209.0%.
NewGenIvf Group Limited (NIVF) reported an operating income of $-10.7M, resulting in an operating profit margin of -226.9%. This margin reflects the operational efficiency of the business before interest and taxes.
NewGenIvf Group Limited (NIVF) generated $1.0M in gross profit for the year, representing a gross profit margin of 20.2%. This demonstrates the company's core pricing power and production efficiency.